Last updated: July 23, 2026
What is the Axsome Malta v. Aurobindo Pharma USA (2:24-cv-04002) lawsuit about?
Executive summary: Case 2:24-cv-04002 is a federal patent infringement action filed by Axsome Malta Ltd. against Aurobindo Pharma USA, Inc. The dispute centers on IP for an FDA-regulated pharmaceutical product implicated by ANDA Paragraph IV-type litigation dynamics and is being litigated in the U.S. District Court under the federal patent statute and Hatch-Waxman framework.
Core litigation fact pattern (high level):
- Parties:
- Plaintiff: Axsome Malta Ltd.
- Defendant: Aurobindo Pharma USA, Inc.
- Case number: 2:24-cv-04002
- Nature: Patent infringement litigation tied to a generic applicant’s FDA pathway entry risk, consistent with Hatch-Waxman timing and structure.
Because the docket content, complaint-specific asserted patent list, claim charts, and any settlement terms are not included in the prompt, only the case identity and litigation posture can be stated without inventing claim-level specifics.
When was 2:24-cv-04002 filed, and what is the procedural posture?
Executive answer: The case is already docketed as 2:24-cv-04002 in 2024 (per the case numbering and user-provided caption). The prompt does not provide the filing date, service date, scheduling order, or current motion status.
Key procedural components that typically drive outcomes in this posture:
- Claim construction schedule (if Markman has occurred or is set)
- Motion practice (Rule 12, transfer/venue, infringement/invalidity motions)
- Expert disclosure timelines
- Summary judgment or trial readiness milestones
No docket dates, order names, or current event status are provided in the input, so a precise timeline cannot be produced without fabricating.
Which patents are asserted in Axsome Malta v. Aurobindo Pharma USA, and what do the claims cover?
Executive answer: The prompt does not include the asserted patent numbers, publication/application references, or claim themes. Without the complaint’s asserted portfolio, any patent-by-patent mapping would be speculative.
What the analysis would normally include once the asserted patents are known:
- Patent category split:
- Composition/formulation patents
- Method-of-use patents
- Device or system patents (rare in ANDA cases)
- Manufacturing/process patents
- Claim elements most likely to be contested:
- Infringement element-by-element
- Anticipation/obviousness structures
- Written description and enablement
- Relationship to Orange Book listings (if the patents are Orange Book delisting or listed)
The prompt provides no patent list; therefore no claim-level infringement/validity analysis is performed.
What defenses does Aurobindo Pharma USA typically raise in Hatch-Waxman Paragraph IV cases like this?
Executive answer: In Paragraph IV-style infringement actions, the recurring defense set is usually:
- Noninfringement (literal and equivalence arguments)
- Invalidity (anticipation, obviousness, lack of written description/enablement)
- Inequitable conduct (less common but present in some cases)
- Jurisdiction/standing/technical statutory defenses depending on posture
The prompt includes no motion filings or defense strategy documents, so this section describes the usual defense landscape but cannot state which defenses are actually pleaded in 2:24-cv-04002.
How strong is Axsome Malta’s patent estate in this case?
Executive answer: Strength cannot be quantified from the prompt because the asserted patents, their expiration dates, claim scopes, and any prior art positions are not provided.
What strength scoring would require (and why it is not possible here):
- Remaining term for each asserted patent
- Federal Circuit vs district court history for similar claims
- Prior litigation outcomes for the same patents
- Claim construction history and district court interpretive trends
- Procedural posture (early-stage motions vs later-stage invalidity rulings)
No portfolio specifics are provided, so no strength analysis is produced.
What is the likely impact on FDA approval and generic launch timing for Aurobindo?
Executive answer: A Hatch-Waxman patent infringement suit typically triggers automatic 30-month stay timing if tied to an ANDA and if the suit meets statutory requirements. Launch timing impact depends on:
- Whether the case was filed within the statutory window
- Whether a stipulated dismissal or settlement occurred
- Whether the court issues a stay pending appeal or a final judgment
- Whether the ANDA is designating “non-infringement” or “invalid” and the Orange Book status
The prompt does not provide the FDA pathway, the specific ANDA number, the asserted Orange Book patents, or any court orders on stay. No launch timing analysis beyond the general Hatch-Waxman mechanism can be performed.
Has the case reached settlement, dismissal, or stipulated injunction terms?
Executive answer: The prompt provides no settlement or dismissal information. Without docket event data, this cannot be determined.
In these cases, settlement outcomes typically take one of these forms:
- Dismissal without prejudice or with prejudice
- Consent judgment with a stipulated “date certain” entry
- Carve-outs for specific strengths, dosages, or indications
- License terms allowing an authorized generic or continued supply after exclusivity windows
No such facts are included, so no settlement analysis is provided.
What does the court’s docket suggest about motion practice and next litigation steps?
Executive answer: No docket entry text is provided. Therefore:
- No statement can be made about pending motions (e.g., transfer, to dismiss, summary judgment)
- No statement can be made about claim construction schedule
- No statement can be made about expert discovery completion
- No statement can be made about trial date or dispositive rulings
How does this litigation compare with other Aurobindo ANDA patent cases (portfolio and enforcement patterns)?
Executive answer: Comparison requires at least one of:
- the asserted drug name/active ingredient
- the ANDA product
- the asserted patent numbers
- the court’s specific findings or claim construction
None of these are provided, so cross-case comparison cannot be performed without inventing connections.
Key takeaways
- 2:24-cv-04002 is a federal patent litigation brought by Axsome Malta Ltd. against Aurobindo Pharma USA, Inc.
- The prompt provides no asserted patent list, no complaint claims, no procedural timeline, and no settlement/dismissal information.
- As a result, this summary can only confirm case identity and litigation framing at a high level; it cannot produce a patent-by-patent infringement/invalidity analysis or a launch-timing forecast grounded in the actual asserted patents and docket orders.
FAQs
-
What is case 2:24-cv-04002’s court jurisdiction and filing basis?
Federal patent infringement jurisdiction under the Hatch-Waxman framework is consistent with the caption structure, but the prompt does not provide jurisdictional allegations or statutory basis language.
-
What happens to an ANDA when a Paragraph IV lawsuit like this is filed?
It commonly triggers an FDA stay of approval pending litigation, depending on filing timing and statutory prerequisites, but the prompt does not provide the ANDA pathway details.
-
Does settlement typically include a “date certain” for generic entry?
Often yes in Hatch-Waxman resolutions, but no settlement terms are provided for this case.
-
Which claims are usually targeted: composition, formulation, or method-of-use?
Patent cases commonly assert composition/formulation and/or method-of-use, but the prompt does not include the asserted patent categories for 2:24-cv-04002.
-
How can investors or licensors estimate infringement risk without knowing the asserted patents?
They usually cannot do so reliably. A risk assessment requires the asserted patent list, remaining term, and claim constructions or prior rulings, none of which are included in the prompt.
References
- Case docket caption provided in prompt: AXSOME MALTA LTD. v. AUROBINDO PHARMA USA, INC., No. 2:24-cv-04002 (U.S. District Court).
